Preventing Microalbuminuria in Type 2 Diabetes
Top Cited Papers
- 4 November 2004
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (19) , 1941-1951
- https://doi.org/10.1056/nejmoa042167
Abstract
The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–enzyme inhibitors and non-dihydropyridine calcium-channel blockers, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion.Keywords
This publication has 35 references indexed in Scilit:
- Regression of Microalbuminuria in Type 1 DiabetesNew England Journal of Medicine, 2003
- Albuminuria and Vascular Damage — The Vicious TwinsNew England Journal of Medicine, 2003
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational studyBMJ, 1997
- The diagnosis of renal involvement in non-insulin-dependent diabetes mellitusCurrent Opinion in Nephrology and Hypertension, 1997
- Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimensArchives of internal medicine (1960), 1991
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesNew England Journal of Medicine, 1984